PDCD1 and melanoma: Notably, studies have shown that VISTA expression in immune cells can increase following IC inhibition in melanoma patients [237], suggesting that the negative regulation by VISTA may represent a critical potential mechanism of acquired resistance in cancer patients treated with PD-1 blockade.